Johnson & Johnson, already a big player in neuroscience drugs, is adding to its portfolio and pipeline with a deal to acquire ...

Groundbreaking research reveals potential link between cytomegalovirus (CMV) and Alzheimer's disease, offering new insights ...

Acquisition includes CAPLYTA® (lumateperone), the first and only U.S. FDA-approved treatment for bipolar I and II depression as an adjunctive and monotherapy; also approved for the treatment of schizo ...

While many people take supplements for brain health, the research supporting supplemental nutrients' effects on brain health ...

Nootropics are touted as “smart drugs” meant to improve cognitive performance. But there’s a lot we still don’t know about ...